SEC ends Dr. Reddy’s (NYSE: RDY) investigation without enforcement action
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories Limited reports that the U.S. Securities and Exchange Commission has concluded its investigation into earlier anonymous allegations of improper payments to healthcare professionals in Ukraine and other markets. The SEC’s letter dated February 23, 2026 states it does not intend to recommend any enforcement action against the company at this time.
The company notes that the SEC’s communication, issued under Securities Act Release No. 5310, should not be read as an exoneration or a guarantee that no action will ever result, but it does indicate that the current investigation is being closed without an enforcement recommendation.
Positive
- SEC closes investigation without enforcement recommendation – The SEC’s February 23, 2026 letter states it has concluded its investigation into prior anti-corruption allegations involving Dr. Reddy’s Laboratories and does not intend to recommend any enforcement action against the company at this time, reducing a significant regulatory uncertainty.
Negative
- None.
Insights
SEC closes probe without enforcement, easing regulatory overhang.
Dr. Reddy’s Laboratories discloses that the SEC has ended its investigation into prior anti-corruption allegations and does not currently plan to recommend enforcement action. This follows several years of cooperation, document production, and engagement with U.S. and Indian regulators.
The letter is explicitly issued under Securities Act Release No. 5310, which clarifies that such notices are not formal exonerations and do not guarantee that future action is impossible. Still, closing an active investigation without an enforcement recommendation typically reduces perceived regulatory uncertainty.
Investors may focus on how the conclusion of this investigation affects the company’s compliance narrative and ongoing interactions with the U.S. Department of Justice and SEBI, as those are mentioned as separate authorities previously notified in connection with the same matter.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
Exhibit |
|
|
Number |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated February 24, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED | ||
| (Registrant) | ||
|
|
|
|
Date: February 24, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. |
8-2-337, Road No. 3, Banjara Hills | |
Hyderabad – 500 034, Telangana, India | |
| |
CIN: L85195TG1984PLC004507 | |
Tel: + 91 40 4900 2900 | |
Fax: + 91 40 4900 2999 | |
Email: mail@drreddys.com | |
Web: www.drreddys.com |
February 24, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/ Madam,
Sub: | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) |
This is in furtherance to the Company’s intimation dated November 19, 2020, and the continuing disclosures made as notes to the quarterly financial results and the audited financial statements filed with exchanges thereafter, wherein it was informed that the Company commenced a detailed investigation into an anonymous complaint about allegation of improper payments to healthcare professionals in Ukraine and potentially in other countries, which could constitute violation of U.S. anti-corruption laws, including the U.S. Foreign Corrupt Practices Act. The matter was accordingly disclosed to the US Department of Justice (“DOJ”), United States Securities and Exchange Commission (“SEC”) and Securities Exchange Board of India (“SEBI”). It was also informed that, at the directions of the committee of the Company's Board of Directors, the Company had engaged a U.S. law firm to conduct the investigation. The Company had further disclosed that such investigations could result in government or regulatory enforcement actions against the Company in the United States and/or foreign jurisdictions and can also lead to civil and criminal sanctions under applicable laws.
Subsequent to the above disclosure to DOJ, SEC and SEBI, the Company has fully cooperated with the said authorities, including by providing requested documents and information and has continued to engage with the SEC and DOJ through various submissions and presentations relating to the initial complaint as well as additional complaints concerning certain other markets.
In this regard, the Company wishes to inform that it has received a letter from the SEC dated February 23, 2026, stating that, based on the information available to it, the SEC has concluded the above-referenced investigation and does not intend to recommend any enforcement action against the Company at this time.
The letter further notes that the communication has been issued pursuant to the guidelines set out in the final paragraph of Securities Act Release No. 5310, which provides, inter alia, that such notice must not be construed as an indication that the party has been exonerated or that no action may ultimately result from the staff’s investigation.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
FAQ
What did Dr. Reddy’s Laboratories (RDY) announce in its February 2026 Form 6-K?
What was the SEC investigating at Dr. Reddy’s Laboratories (RDY)?
What is the outcome of the SEC investigation into Dr. Reddy’s Laboratories (RDY)?
Does the SEC letter fully exonerate Dr. Reddy’s Laboratories (RDY)?
Which regulators were informed about the anti-corruption allegations at Dr. Reddy’s (RDY)?
How long has Dr. Reddy’s Laboratories (RDY) been disclosing this investigation?
Filing Exhibits & Attachments
1 documentPress Releases
